NEUROCRINE Biosciences Comeback !

Neurocrine Bio (NasdaqGS: NBIX - News) recently entered a deal with Abbott, which paid Neurocrine $75 million upfront, with the potential for another $500 million plus royalties still to come.

The partnership is a homerun in our view. Abbott is the ideal partner for Neurocrine with elagolix. The news comes less than a month after the phase II DAISY-901 program offered up positive data on all primary and secondary endpoints for the treatment of endometriosis.

We expect Abbott to be in position to initiate the phase III program on elagolix in endometriosis by the end of the year.  

Drugmakers Finally Recognize the Next Big Opportunity

By Kris Eddy
June 23, 2010 | Comments (1)



ShareThis
NBIX

Neurocrine Biosc
Rate NBIX
CAPS Rating 1/5 Stars

Up $6.16 $0.42 (7.32%)
More about NBIX

   * San Diego's Neurocrine Biosciences Scores Second Big Deal in Two Days
   * Double-Digit Rise on Doubling Its Cash
   * BROWSE ALL NBIX ARTICLES



   

The drug flibanserin, from Boehringer Ingleheim, gets a lot of publicity, perhaps because it has to do with sex. It's the so-called "pink Viagra," a pill that might enhance women's libido. The bad news, reported by The Wall Street Journal, is that a Food and Drug Administration advisory panel last week unanimously rejected it, voicing concerns about safety.

The good news is that flibanserin is just one example of how drug companies are increasing efforts to address women's health issues, arguably the next big opportunity in health care.

"Pharmaceutical companies are beginning to focus more on how drugs can affect both men and women," Lisa LaMotta of Minyanville recently wrote. "Many companies are even addressing more of the problems that are unique to women -- gynecological issues, osteoporosis, menopause, and even female sexual desire."

LaMotta notes among others:

   * BioSante Pharmaceuticals has a female-desire drug in late-stage trials.
     Merck (NYSE: MRK) and GlaxoSmithKline (NYSE: GSK) offer human papillomavirus (HPV) vaccines (Gardasil and Cervarix, respectively).
   * Abbott Laboratories (NYSE: ABT) recently signed a marketing agreement with Neurocrine Biosciences (Nasdaq: NBIX) for an endometriosis-related pain treatment.
   * Teva Pharmaceutical manufactures several birth control pills.

Gardasil brought Merck more than $1.1 billion in sales in 2009, down from 2007 and 2008 levels that each clocked in at over $1.4 billion. Glaxo's Cervarix, approved in the U.S. only in October 2009, has contributed to strong growth in the company's vaccine business. Abbott is paying Neurocrine up to $575 million for rights to Neurocrine's experimental drug, and will make royalty payments if the drug gets to market.

If one of these companies could develop a pill that solves hot flashes, it could probably bring in $2 billion annually, easy.

Now is a good time for women's health care to claim some of the spotlight shining on the desire to improve health.  

wow....!  

Neurocrine meldet enttäuschende Phase 2b Studiendaten (Tourette)

https://endpts.com/...ailure-for-tourette-syndrome-study-shares-sink/

 

Neurocrine meldet Zahlen für 2018

• 2018 Umsatz ~451 Mio. $ (vgl. 2017 ~162 mio. $)
  
  • INGREZZA ~410 Mio. $
    
  • Collaboration revenue ~42 Mio. $
    
• 2018 Gewinn ~21 Mio. $ (vgl. 2017 ~143 Mio. $ Verlust)
  
• 2019 Ausblick: SG&A / R&D ~550-600 Mio. $
  
• Collaboration mit Voyager Therapeutics
  

http://phoenix.corporate-ir.net/...;p=irol-newsArticle&ID=2386180

 

Waren der hier die Erwartungen wieder höher?

(Grund meines Interesses: an dem Wert: Habe gelesen, dass Neurocrine ein wichtiges Investment von BB Biotech ist!